Literature DB >> 18955560

Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.

Eva Ajzner1, Agota Schlammadinger, Adrienne Kerényi, Zsuzsanna Bereczky, Eva Katona, Gizella Haramura, Zoltán Boda, László Muszbek.   

Abstract

Acquired factor XIII (FXIII) deficiency due to autoantibody against FXIII is a very rare severe hemorrhagic diathesis. Antibodies directed against the A subunit of FXIII, which interfere with different functions of FXIII, have been described. Here, for the first time, we report an autoantibody against the B subunit of FXIII (FXIII-B) that caused life-threatening bleeding in a patient with systemic lupus erythematosus. FXIII activity, FXIII-A(2)B(2) complex, and individual FXIII subunits were undetectable in the plasma, whereas platelet FXIII activity and antigen were normal. Neither FXIII activation nor its activity was inhibited by the antibody, which bound to structural epitope(s) on both free and complexed FXIII-B. The autoantibody highly accelerated the elimination of FXIII from the circulation. FXIII supplementation combined with immunosuppressive therapy, plasmapheresis, immunoglobulin, and anti-CD20 treatment resulted in the patient's recovery. FXIII levels returned to around 20% at discharge and after gradual increase the levels stabilized above 50%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955560     DOI: 10.1182/blood-2008-09-179333

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Acquired FXIII inhibitors: a systematic review.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

Review 2.  [Factor XIII : Pharmacodynamic and pharmacokinetic characteristics].

Authors:  E H Adam; S Kreuer; K Zacharowski; C F Weber; R Wildenauer
Journal:  Anaesthesist       Date:  2017-01       Impact factor: 1.041

3.  Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.

Authors:  Masatake Matsuoka; Tokifumi Majima; Tomohiro Onodera; Masahiro Ieko; Masayoshi Souri; Akitada Ichinose; Takashi Kurita; Yasuhiko Kasahara; Masahiro Inoue; Daisuke Takahashi
Journal:  Int J Hematol       Date:  2012-10-16       Impact factor: 2.490

4.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

5.  Functional factor XIII-A is exposed on the stimulated platelet surface.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Steven R Fraser; Claire S Whyte; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

Review 6.  Bleeding related to disturbed fibrinolysis.

Authors:  Krasimir Kolev; Colin Longstaff
Journal:  Br J Haematol       Date:  2016-08-01       Impact factor: 6.998

7.  Knee hemarthrosis after arthroscopic surgery in an athlete with low factor XIII activity.

Authors:  Akira Tsujii; Yoshinari Tanaka; Yasukazu Yonetani; Yoshiki Shiozaki; Yoshiaki Tomiyama; Shuji Horibe
Journal:  Sports Med Arthrosc Rehabil Ther Technol       Date:  2012-10-02

8.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28

Review 9.  Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.

Authors:  Fahad S M Alshehri; Claire S Whyte; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.